SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation of $0 in Q1 FY2026
Q1 FY2026 stock-based compensation was $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.79M USD
- Year-over-year change
- —
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.79M | — |
Stock-Based Compensation vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $80.22M USD | +36.6% | +17.9% | 13.1% | |
| LTM Jun 2026 | $72M USD | -33.9% | +33.9% | 1.4% | |
| LTM Mar 2026 | $48.31M USD | +35.8% | +36.5% | 92.8% | |
| LTM Sep 2026 | $42M USD | -154.5% | +5.0% | 0.4% | |
| LTM Mar 2026 | $32.42M USD | +19.7% | +40.5% | 25.4% | |
| LTM Mar 2026 | $31.69M USD | -0.5% | +25.3% | 416.2% | |
| LTM Apr 2026 | $29.4M USD | +9.3% | +14.5% | 10.1% | |
| LTM Mar 2026 | CHF 18.42M CHF | +63.4% | +171.2% | 3653.8% | |
| LTM Mar 2026 | $11.67M USD | -30.6% | +0.2% | 14.7% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $2.79M USD | — | — | — |
| Peer median (excluding SGP) | — | +9.3% | +25.3% | 14.7% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (39.87M) |
| Depreciation & Amortization | 612K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.79M |
| Change in Working Capital | 2.45M |
| Accounts Receivables | (8K) |
| Inventory | 0 |
| Accounts Payables | 549K |
| Other Working Capital | 1.91M |
| Other Non-Cash Items | 1.32M |
| Operating Cash Flow | (32.7M) |
| Capital Expenditures | (789K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (17M) |
| Sales of Investments | 6M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (11.79M) |
| Debt Repayment | 0 |
| Common Stock Issued | 170K |
| Common Stock Repurchased | (1.45M) |
| Dividends Paid | 0 |
| Other Financing Activities | (1.47M) |
| Financing Cash Flow | 124.59M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | 80.09M |
| Free Cash Flow | (33.49M) |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.